Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT06121180 2025-12-04

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Phase 2 Recruiting

32 enrolled

Dermatologic

Uveal Melanoma

NCT04315701 2025-11-20

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

Phase 2 Active not recruiting

35 enrolled

Dermatologic

Skin Neoplasms

NCT05574101 2025-08-08

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

Phase 2 Active not recruiting

34 enrolled

Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms

NCT03132636 2025-04-08

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Phase 2 Completed

138 enrolled 21 charts 2 FDA

Dermatologic

Carcinoma, Basal Cell

NCT04291105 2025-03-26

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Phase 2 Recruiting

87 enrolled

DermatologicGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Melanoma

NCT04679480 2024-07-30

Anti-PD1-antibody and Pulsed HHI for Advanced BCC

Phase 2 Active not recruiting

20 enrolled

Dermatologic

Carcinoma, Basal Cell

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT02423863 2020-12-17

Poly-ICLC

Phase 2 Completed

26 enrolled

DermatologicHead & NeckSarcoma

Head and Neck Neoplasms, Melanoma, Neoplasms, Sarcoma

Clinical Trials

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

CEMI-first

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NeoMatryx

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Anti-PD1-antibody and Pulsed HHI for Advanced BCC

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Poly-ICLC